Skip to main content

Table 4 Pt, As, and Se amounts in 24-h urine as metal · (g creatinine) -1 results for the group patients treated with Pt-based drugs and control group treated without Pt-based drug and the baseline group (a)

From: Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs

Groups

Type of cancer

Parameter

μg Pt/g Cr

μg Se/g Cr

ng As/g Cr

Cisplatin (Group 1)

Lung

X

1.05

143.0

5.57

Med

1.06

49.0

2.08

DS

0.625

263.0

8.94

n

32

24

21

Min

0.136

7.0

0.360

Max

2.52

1028.0

31.1

Cisplatin (Group 2)

Other

X

1.39

83.9

7.96

Med

0.969

40.7

2.55

DS

1.59

186.0

17.1

n

47

36

31

Min

0.110

11.3

0.280

Max

7.26

1136.0

91.2

Carboplatin (Group 3)

Other

X

13.3

156.0

10.1

Med

a

a

a

DS

9.76

182.0

18.5

n

11

9

6

Min

0.780

25.5

0.40

Max

32.5

484.0

47.7

Control 1 (b) (Group 4)

Other

X

 

51.6

 

Med

 

a

 

DS

 

33.7

 

n

 

7

 

Min

 

5.30

 

Max

 

92.3

 

Control 2 (c) (Group 5)

Lung and other

X

 

61.9

 
  

Med

 

a

 
  

DS

 

20.4

 
  

n

 

9

 
  

Min

 

28.1

 
  

Max

 

90.4

 
  1. Pt, As and Se amounts in 24-h urine samples expressed as metal (g creatinine)–1
  2. Supp, Supplied; X, mean; Med, Median; SD, Standard deviation; n, number of cases; Min, Minimum value; Max, Maximum value; (a) due the small number of cases, the median values were not reported; (b) non platinum drugs treatment; (c) patients without chemotherapy (two gastric cancer, two bladder cancer and five lung cancer).